Source: Annual Congress 2007 - Pulmonary infections in the immunocompetent and immunocompromised host
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
K. Dimakou, K. Tsikritsaki, K. Sagris, I. Dimitroulis, E. Akoumianaki, M. Toumbis (Athens, Greece). The effect of nebulised colistimethate sodium on non-CF bronchiectasis with pseudomonas aeruginosa (preliminary report). Eur Respir J 2007; 30: Suppl. 51, 2573

Member's Comments

No comment yet.

Related content which might interest you: The effect of tobramycin nebulised solution in COPD patients with Pseudomonas aeruginosa in sputum (preliminary report) Source: Eur Respir J 2004; 24: Suppl. 48, 409s Year: 2004 Non-CF bronchiectasis: nebulised colistimethate sodium improves symptoms and bacterial load in sputum of patients with pseudomonas aeruginosa Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Source: Eur Respir J 2002; 20: 658-664 Year: 2002 Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011 Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013 Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy Year: 2020 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Source: Eur Respir J 2013; 41: 1107-1115 Year: 2013 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007 Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Distribution of nebulised gentamicin in patients with bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study Source: Eur Respir J, 57 (1) 2001451; 10.1183/13993003.01451-2020 Year: 2021